Compare · AZN vs PRGO
AZN vs PRGO
Side-by-side comparison of AstraZeneca PLC (AZN) and Perrigo Company plc (PRGO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and PRGO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $542.54B, about 382.5x PRGO ($1.42B).
- Over the past year, AZN is down 7.1% and PRGO is down 61.3% - AZN leads by 54.2 points.
- Both names hit the wire about 15 times in the past 4 weeks.
- AZN has more recent analyst coverage (25 ratings vs 11 for PRGO).
- Company
- AstraZeneca PLC
- Perrigo Company plc
- Price
- $174.90-1.68%
- $10.25+0.89%
- Market cap
- $542.54B
- $1.42B
- 1M return
- -5.32%
- -3.44%
- 1Y return
- -7.11%
- -61.34%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2026
- News (4w)
- 15
- 15
- Recent ratings
- 25
- 11
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Perrigo Company plc
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through Consumer Self-Care Americas, Consumer Self-Care International, and Prescription Pharmaceuticals segments. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the brand names of Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, and Dr. Fresh. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 30 countries, primarily in Europe. The Prescription Pharmaceuticals segment develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, controlled substances, injectable, hormones, oral solid dosage forms, and oral liquid formulations in the United States, as well as pharmaceutical and diagnostic products in Israel. In addition, it offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Latest AZN
- Officer Sharma Mani was granted 1 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,263 units (SEC Form 4)
- SEC Form 6-K filed by AstraZeneca PLC
- TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
- NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
- Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
Latest PRGO
- Director Parker Geoffrey M. exercised 976 units of Ordinary Shares at a strike of $10.99 and covered exercise/tax liability with 469 units of Ordinary Shares, increasing direct ownership by 2% to 33,217 units (SEC Form 4)
- SEC Form 4 filed by Interim President and CEO Manzone Albert
- Director Alford Bradley A exercised 976 units of Ordinary Shares at a strike of $10.99 and covered exercise/tax liability with 469 units of Ordinary Shares, increasing direct ownership by 1% to 45,465 units (SEC Form 4)
- SEC Form SD filed by Perrigo Company plc
- Former CEO and director Lockwood-Taylor Patrick exercised 25,230 units of Ordinary Shares at a strike of $10.83 and covered exercise/tax liability with 12,906 units of Ordinary Shares, increasing direct ownership by 11% to 123,170 units (SEC Form 4)
- Perrigo Company plc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure
- Perrigo Announces Leadership Transition
- EVP and President of CSCI Khoury Roberto exercised 17,902 units of Ordinary Shares at a strike of $10.83 and covered exercise/tax liability with 9,346 units of Ordinary Shares, increasing direct ownership by 164% to 13,761 units (SEC Form 4)
- EVP & CHRO Willis Robert exercised 3,441 units of Ordinary Shares at a strike of $10.83 and covered exercise/tax liability with 1,797 units of Ordinary Shares, increasing direct ownership by 3% to 50,568 units (SEC Form 4)
- EVP and CSO Lennox Abigail exercised 3,823 units of Ordinary Shares at a strike of $10.83 and covered exercise/tax liability with 1,996 units of Ordinary Shares, increasing direct ownership by 66% to 4,607 units (SEC Form 4)